BIOJECT



California Office:

26212 Dimension Drive, Ste 260
Lake Forest, CA 92630
949-273-8643

Oregon Office:

7180 SW Sandburg Street, Ste 100
Tigard, Oregon 97223
503-692-8001

Customer Service:

800-683-7221 ext 4122

Press Releases

2015

Date

Title

03/03 Bioject Mexico Distribution
03/03 UTEP USAID RVF Africa
02/12 Management Change

 

 

2013 & 2014

Date

Title

12/22 Bioject Receives Medical Device Registration in Nigeria
12/18 Bioject Receives Medical Device Registration in the Philippines
12/15 Bioject and Immunomic Therapeutics Agreement
11/10 Bioject Reports Unaudited Third Quarter 2014 Financial Results
10/20 Bioject Announces Formation of Bioject LTD
05/29 Needle-free: Bioject Crafts Injection Tools
05/27 Bioject to Participate in World Vaccine Congress in Singapore
05/12 Bioject Announces the Appointment of a Distributor for China
04/22 Bioject Adds to Its Global Distribution Network
03/20 Bioject Seeking to Restructure Its Balance Sheet
03/13 Bioject Reports Unaudited Year-End and Fourth Quater 2013 Financial Results
01/22 Bioject's Distributor Meditrend International Receives Australian Device Registration
11/14 Bioject Reports Unaudited Third Quarter 2013 Financial Results
10/30 Bioject Enters Into Distribution Agreement with FlashMed Inc. in Ecuador
10/23 Bioject Enters Into Agreement with Fondaco PTE LTD for Distribution of Full Line of Needle Free Injection Devices in Asia
10/03 iHealthnet Announces Introduction of Bioject's Needle-free Injection Systems in Nigeria
09/03  Bioject and iHealthNet Enter Into Distribution Agreement
08/16  Bioject Reports Unaudited Second Quarter 2013 Financial Results
07/12  Bioject Medical Technologies to be featured on "21st Century Health" on July 14, 2013 on  Bloomberg International
05/17  Bioject Reports Unaudited First Quarter 2013 Financial Results
05/07  Bioject Participates in Defense Contract Award
03/21  Bioject Enters into Three Distribution Agreements
02/11  Bioject Reports Unaudited Year-End and Quarterly 2012 Financial Results

2012

Date

Title

07/20

Bioject Reports Unaudited Year-End 2011 and First Quarter 2012 Financial Results

01/17

Bioject Retains Financial Advisor to Explore Strategic Alternatives

2011

Date

Title

11/10

Bioject Announces Change in President and Chief Executive Officer

11/08

Bioject Reports Third Quarter 2011 Financial Results

10/24

FDA Communication on Use of Jet Injectors with Influenza Vaccines

09/12

Bioject ZetaJet to be Utilized by Publix for Flu Season Immunizations

09/07

Fred Meyer to Offer Needle-Free Flu Vaccines for First Time

08/10

Bioject Reports Second Quarter 2011 Financial Results (Audio)

08/10

Bioject Reports Second Quarter 2011 Financial Results

08/03

Bioject to Report Second Quarter 2011 Financial Results

06/13

2011 Shareholder's Meeting

06/09

2011 Shareholder's Meeting (Audio)

06/02

Notice of Annual Shareholder Meeting

05/11

Bioject Reports First Quarter 2011 Financial Results (Audio)

05/11

Bioject Reports First Quarter 2011 Financial Results

05/04

Bioject to Report First Quarter 2011 Financial Results

04/22

2010 Annual Report and Proxy

03/25

Fourth Quarter and Fiscal Year 2010 Results (Audio)

03/23

Bioject Reports Fourth Quarter and Year-End 2010 Financial Results
03/17 Bioject to Report Fourth Quarter and Year-End 2010 Financial Results
02/09 Bioject Announces Collaboration to Provide Needle-free Pen Injector  for Intradermal Delivery Studies

 

2010

Date Title
11/10 Bioject Reports Third Quarter 2010 Financial Results
11/03 Bioject to Report Third Quarter 2010 Financial Results
09/28 Biojector®2000 Utilized in a Human Clinical Trial of DNA-MVA HIV Vaccine
08/05 Bioject Reports Second Quarter 2010 Financial Results (Audio)
08/04 Bioject Reports Second Quarter 2010 Financial Results
07/28 Bioject to Report Second Quarter 2010 Financial Results
07/08 Bioject’s Intradermal Needle-Free Delivery System Used in World Health Organization Clinical Trial in Oman with Poliovirus Vaccine
06/10 2010 Annual Meeting of Shareholders (Audio)
06/04 Bioject Medical Technologies Inc. Annual Shareholder Meeting Thursday, June 10, 2010
05/13 Bioject Reports First Quarter 2010 Financial Results (Audio)
05/12 Bioject Reports First Quarter 2010 Financial Results
05/05 Bioject to Report First Quarter 2010 Financial Results
04/28 Bioject Announces Results of Intradermal Dose Sparing Influenza Study Conducted by the Centers for Disease Control and Prevention
04/27 Bioject Announces Results from US Navy Study for a Malaria Vaccine
04/26 2009 Annual Report
04/26 2010 Proxy
04/07 Bioject Meets Final Development Milestone for Merial Ltd
03/17 Bioject Reports December 31, 2009 Results
02/22 Cyto Pulse, the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Volunteers
02/16 MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine
01/05 Bioject Establishes Strategic Alliance with MPI Research

 

2009

Date Title
12/21 Bioject Closes Previously Announced Equity Financing
11/05 Bioject Reports Third Quarter 2009 Results (Audio)
11/04 Bioject Reports Third Quarter 2009 Results
10/30 Bioject to Report Third Quarter 2009 Financial Results
08/06 Bioject Reports Second-Quarter 2009 Financial Results (Audio)
08/05 Bioject Reports Second-Quarter 2009 Financial Results
05/06 Bioject Reports First Quarter 2009 Financial Results
05/05 Bioject Signs CRADA with US Navy to Study a Malaria Vaccine
04/14 Bioject Meets Milestone for Merial Limited
04/06 Bioject Announces FDA Market Clearance for the Zetajet™ Needle-Free Injection Therapy System
03/27 Fourth Quarter and Year-End 2008 Financial Results (Audio)
03/25 Bioject Reports December 31, 2008 Results
02/24 Bioject Enters into a Collaborative Research Agreement with IAVI for the Delivery of an HIV Vaccine Candidate
02/10 Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.

 

2008

Date Title
12/09 SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
11/10 Bioject Reports Third-Quarter 2008 Results
11/06 U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
08/19 Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
08/06 Bioject Reports Second-Quarter 2008 Financial Results
07/22 Bioject to Be Transferred to the over-the-Counter Bulletin Board
07/17 Biojector®2000 Data Presented in Vical’s Pandemic Influenza DNA Vaccine Human Trial
06/23 Bioject Announces Long-Term Agreement With Merial Limited
06/05

Bioject and ImmunoVaccine Technologies Announce Research Collaboration

05/27 Biojector®2000 Technology Put to the Test in CDC Flu Vaccine Study
05/23 Bioject Receives Nasdaq Staff Detemination
05/07 First Quarter 2008 Earnings Release
03/17 Bioject Reports December 31, 2007 Results and Initiates New Strategy

 

About Us | Products | Focus AreasContact Bioject | Resources & News

 Copyright © 2012 Bioject. All rights reserved.